Literature DB >> 304844

Characterization of the immunoprotective antigen of ribosomal preparations from Haemophilus influenzae.

R P Tewari, M Lynn, A J Birnbaum, M Solotorovsky.   

Abstract

This investigation was designed to characterize the immunoprotective antigen of ribosomal preparations from Haemophilus influenzae. The ribosomes that elicited 80 to 90% protection contained 25% protein and 75% ribonucleic acid but did not contain any detectable hexoses. The immunodiffusion and hemagglutination inhibition tests also failed to demonstrate that the capsular material (polyribose phosphate) was in ribosomal preparations. Treatment of ribosomes with ribonuclease degraded 78% ribonucleic acid but did not affect the immunogenicity of such preparations. The proteolytic enzymes reduced the immunogenicity of ribosomes corresponding to the amount of protein degraded. The protection elicited by ribosomal protein extracted with 2-chloroethanol was comparable to that induced by intact ribosomes. In contrast, the low levels of protection observed by immunization with phenol-extracted ribonucleic acid were dependent on the amounts of contaminating protein. Finally, immunogenicity of ribosomal ribonucleic acid and protein was abrogated by treatment with proteolytic enzymes. These results clearly indicate that the protein associated with Haemophilus ribosomes is the major immunoprotective antigen.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 304844      PMCID: PMC414048          DOI: 10.1128/iai.19.1.58-65.1978

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  34 in total

1.  Biological properties of an immunogenic pneumococcal subcellular preparation.

Authors:  H C Thompson; T K Eisenstein
Journal:  Infect Immun       Date:  1976-03       Impact factor: 3.441

2.  Evidence for an extrinsic immunogen in effective ribosomal vaccines from Salmonella typhimurium.

Authors:  P Hoops; N E Prather; J Berry; J M Ravel
Journal:  Infect Immun       Date:  1976-04       Impact factor: 3.441

3.  Humoral immunity to Streptococcus pneumoniae induced by a pneumococcal ribosomal protein fraction.

Authors:  C L Swendsen; W Johnson
Journal:  Infect Immun       Date:  1976-08       Impact factor: 3.441

Review 4.  Prevention through immunization: new opportunities or end of the road?

Authors:  R M Krause
Journal:  J Infect Dis       Date:  1977-02       Impact factor: 5.226

5.  Immunology of the infant rat experimental model of Haemophilus influenzae type b meningitis.

Authors:  R L Myerowitz; C W Norden
Journal:  Infect Immun       Date:  1977-04       Impact factor: 3.441

6.  Immunoprotective activity of ribosomes from Haemophilus influenzae.

Authors:  M Lynn; R P Tewari; M Solotorovsky
Journal:  Infect Immun       Date:  1977-02       Impact factor: 3.441

7.  Evidence for O antigens as the antigenic determinants in "ribosomal" vaccines prepared from Salmonella.

Authors:  T K Eisenstein
Journal:  Infect Immun       Date:  1975-08       Impact factor: 3.441

8.  Biochemical and immunological properties of ribonucleic acid-rich extracts from Francisella tularensis.

Authors:  I I Andron LA; H T Eigelsbach
Journal:  Infect Immun       Date:  1975-07       Impact factor: 3.441

9.  Immunogenicity of ribosomal vaccines isolated from group A, type 14 Streptococcus pyogenes.

Authors:  W O Schalla; W Johnson
Journal:  Infect Immun       Date:  1975-06       Impact factor: 3.441

10.  Effect of nonspecific stimulation on the defense mechanisms of inbred mice.

Authors:  S Medina; S I Vas; H G Robson
Journal:  J Immunol       Date:  1975-06       Impact factor: 5.422

View more
  15 in total

1.  Role of interferon in mice in protection against influenza A virus by bacterial ribosomes together with membranal glycoproteins of Klebsiella pneumoniae as adjuvant.

Authors:  D Robert; J P Quillon; B Ivanoff; Y Beaudry; R Fontanges; G Normier; A M Pinel; L D D'hinterland
Journal:  Infect Immun       Date:  1979-11       Impact factor: 3.441

2.  Induction of active immunity with membrane fractions from Haemophilus influenzae type b.

Authors:  J P Burans; M Lynn; M Solotorovsky
Journal:  Infect Immun       Date:  1983-07       Impact factor: 3.441

3.  Recombinant L7/L12 ribosomal protein and gamma-irradiated Brucella abortus induce a T-helper 1 subset response from murine CD4+ T cells.

Authors:  S C Oliveira; Y Zhu; G A Splitter
Journal:  Immunology       Date:  1994-12       Impact factor: 7.397

4.  Induction of immunity against lethal Haemophilus influenzae type b infection by Escherichia coli core lipopolysaccharide.

Authors:  M I Marks; E J Ziegler; H Douglas; L B Corbeil; A I Braude
Journal:  J Clin Invest       Date:  1982-04       Impact factor: 14.808

5.  Capsular serotypic specificity of the protection conferred on mice by Klebsiella pneumoniae ribosomal preparations.

Authors:  M Riottot; J M Fournier; J Pillot
Journal:  Infect Immun       Date:  1979-05       Impact factor: 3.441

6.  Serological and biological activities of anti-Haemophilus influenzae ribosomal serum.

Authors:  M Katz; M Lynn; M Solotorovsky
Journal:  Infect Immun       Date:  1981-03       Impact factor: 3.441

7.  Kinetics of Haemophilus influenzae type B infection in normal and ribosome-immunized mice using intraperitoneal and intracerebral routes of inoculation.

Authors:  J P Burans; F H Kruszewski; M Lynn; M Solotorovsky
Journal:  Br J Exp Pathol       Date:  1981-10

8.  Immunogenicity of ribosomal preparations from Neisseria gonorrhoeae.

Authors:  M D Cooper; R P Tewari; D V Bowser
Journal:  Infect Immun       Date:  1980-04       Impact factor: 3.441

9.  Naturally occurring antibodies in human sera that react with Haemophilus influenzae type b ribosomal vaccine.

Authors:  M Lynn; M A Katz; T F Santucci
Journal:  J Clin Microbiol       Date:  1983-05       Impact factor: 5.948

10.  Opsonization and phagocytosis of Haemophilus influenzae type B organisms by mouse polymorphonuclear leucocytes and antiribosomal serum.

Authors:  M A Katz; M Solotorovsky; M Lynn
Journal:  Br J Exp Pathol       Date:  1983-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.